Earendil Labs announces initiation of a phase 1 study of a half-life extended novel anti-TL1A antibody

Overview

Quest Diagnostics, a leader in diagnostic information services, including advanced diagnostics for brain health, announced it plans to offer laboratory testing based on the Lumipulse G pTau 217/ß-Amyloid 1-42 Plasma Ratio in-vitro diagnostic (IVD) test from Fujirebio, a global leader in the field of high-quality IVD testing.

Quest to Launch First FDA-Cleared Blood Test for Alzheimer’s Assessment 

• Quest plans to make the test available to physicians and biopharmaceutical collaborators later this summer. 
• The test is the first blood-based IVD test cleared by the US Food and Drug Administration (FDA) to aid in identifying patients with amyloid pathology associated with Alzheimer's disease. 
• It is designed to aid the clinical assessment of Alzheimer's disease in adult patients aged 50 years and older presenting at a specialized care setting with signs and symptoms of cognitive decline.
• Through its AD-Detect portfolio, Quest provides a suite of advanced lab-developed blood tests regulated under CLIA for assessing patients with cognitive impairment for Alzheimer's disease. The Fujirebio test offering extends this portfolio to include an FDA-cleared option for use in specialized care settings.

Statement from Kathleen Valentine: GM, neurology, Quest Diagnostics

Our goal is to advance access to quality and innovative blood-based tests for Alzheimer's disease. Adding the Fujirebio test to our existing blood-based tests provides the many physicians we serve with another powerful option for assessing patients for Alzheimer's disease,"" said Kathleen Valentine, vice president and general manager, neurology, Quest Diagnostics. 
""Blood-based testing can be less invasive and more convenient than traditional test methods. We are excited to leverage our expansive network of patient service centres to broaden access to the Fujirebio innovation to help more at-risk individuals gain access to the insights they need sooner.""

FDA-Cleared Test Shows High Accuracy in Detecting Amyloid Pathology

In a clinical study population of 499 patients, which closely mirrors US demographics, and when applying a dual cut point, the FDA-cleared test demonstrated a positive predictive value (PPV) of 92% and a negative predictive value (NPV) of 97%, with 20% of patients uncertain to have amyloid pathology, thus requiring further testing.

Quest to Highlight Neurological Testing Advances at AAIC 2025

Quest will showcase its complete line up of Alzheimer's and other neurological test innovations at this year's Alzheimer's Association International Conference (AAIC) in Toronto from July 27-31.

Words from Michael Racke: Quest Diagnostics

As brain health and Alzheimer's disease interventions continue to evolve, diagnosing patients earlier, when interventions can be most effective, is critical,"" said Michael Racke, MD, a board-certified neurologist and medical director of neurology, Quest Diagnostics. ""We are constantly looking for ways to help physicians and patients make the most informed decisions, and this new addition to our test menu will aid that goal.""

Quest Expands Access to Convenient, Less Invasive Alzheimer’s Testing

• While amyloid PET imaging and cerebral spinal fluid testing are established methods for aiding the diagnosis of Alzheimer's disease, they are significantly more expensive, invasive and specialist-dependent than blood-based tests. 
• With a physician's order, patients can conveniently provide a blood draw for testing for the Fujirebio test and any of the AD-Detect tests through Quest's network of patient sites. 
• Quest maintains approximately 8,000 patient access points, including an extensive patient service centre network of approximately 2,000 locations in the US, as well as phlebotomists in physician offices and mobile phlebotomy services. 
• Specimens will be transported for testing to Quest's state-of-the-art laboratory in San Juan Capistrano, California.

Alzheimer's disease globally

• Nearly 7 million Americans have Alzheimer's, the most prevalent dementia, a number projected to reach 14 million by 2060. 
• Approximately 12-18% of adults over the age of sixty are living with mild cognitive impairment, a potential sign of AD. 
• Seventy-seven percent of physicians say new therapies will transform Alzheimer's into a chronic, manageable disease, and 94% of physicians say blood tests would be more cost effective for the healthcare system compared to more invasive methods of detection (e.g., lumbar puncture, imaging studies) according to a special report from Quest.

About the company: Quest Diagnostics

• Quest is committed to developing and offering innovative advanced diagnostics to aid in evaluating Alzheimer's disease and other brain diseases.
• Quest Diagnostics works across the healthcare ecosystem to create a healthier world, one life at a time. 
• The company provide diagnostic insights from the results of our laboratory testing to empower people, physicians and organizations to take action to improve health outcomes.

Earendil Labs announces initiation of a phase 1 study of a half-life extended novel anti-TL1A antibody
Overview
Earendil Labs, an AI-empowered biotechnology company, announced that it has completed cohort 1 dosing in a phase 1 trial for a novel anti-TL1A antibody (HXN-1001). The phase 1 study is designed to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of HXN-1001 in healthy volunteers.

About HXN-1001

• HXN-1001 is a half-life extended next-generation anti-TL1A antibody with great potential for the treatment of patients with inflammatory bowel diseases (IBD), including ulcerative colitis and Crohn's disease,and other immunological disorders. 
• In preclinical studies, HXN-1001 has demonstrated more potent efficacies in multiple in vitro assays and animal models than several benchmark products currently under clinical development. 
• Besides the extended in vivo half-life, HXN-1001 is formulated at high protein concentration for subcutaneous injection. 
• Taken together, HXN-1001 represents a potentially more efficacious and more convenient treatment option for patients with IBD and other immunological disorders.

Words from Zhenping Zhu: President & Co-CEO of Earendil Labs

The initiation of the phase 1 trial for HXN-1001 is a significant achievement on our pursuit of discovering and developing next-generation best-in-class biologics therapeutics"", Zhenping Zhu, MD, PhD, President & Co-CEO of Earendil Labs, commented, ""Our team is working diligently to advance HXN-1001 clinical programs as part of our global strategies to develop innovative treatments for IBD patients.""

Words from Jian Peng: CEO of Earendil Labs

Jian Peng, PhD, CEO of Earendil Labs, stated, ""With HXN-1001 phase 1 initiation, we are officially evolving into a clinical-stage biotech company. This event marks a significant milestone at Earendil Labs. We look forward to engaging and collaborating with the IBD community to further define our development strategy and to fully realize the great potential of HXN-1001.""

About Earendil Labs

• Earendil Labs is a US-based biotech company redefining biopharmaceutical innovation with its cutting-edge AI-powered platform. 
• By combining advanced machine learning, generative protein engineering, and high-throughput experimental techniques, Earendil Labs and its affiliate Helixon Therapeutics streamline the drug discovery & research process with the aim of significantly accelerating drug development. 
• Earendil Labs' proprietary integrated framework enables precise optimization of functionality, manufacturability, and developability of protein-based biologics with first-in-class or best-in-class potential.

Optimize Your trial insights with Clival Database.

Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.

Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.

With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.

To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.

Elevate your trial success rate with the cutting-edge insights from Clival database.

Check it out today and make more informed sourcing decisions! Learn More!